Author: Gupta, Ankur; Pradhan, Anish; Maurya, Vimal K; Kumar, Swatantra; Theengh, Angila; Puri, Bipin; Saxena, Shailendra K
Title: Therapeutic Approaches for SARS-CoV-2 Infection Cord-id: fwqmdenn Document date: 2021_5_5
ID: fwqmdenn
Snippet: Therapeutic approaches to COVID-19 treatment leverage on crucial target proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months of pandemic and yet there is no known specific drugs are available. However, research is progressing with time in terms of high throughput virtual screening (HTVS) and rational design of repurposed, novel synthetic and natural products drug discovery by understanding the viral life cycle, immuno-pathological and clinical outcomes in patients ba
Document: Therapeutic approaches to COVID-19 treatment leverage on crucial target proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months of pandemic and yet there is no known specific drugs are available. However, research is progressing with time in terms of high throughput virtual screening (HTVS) and rational design of repurposed, novel synthetic and natural products drug discovery by understanding the viral life cycle, immuno-pathological and clinical outcomes in patients based on host’s nutritional, metabolic and lifestyle status. Further, complementary and integrative health approaches (CIHA) have also shown to improve the resiliency and immune responses among people. In this article, we summarize about all the therapeutic approaches for COVID-19 antiviral drug discovery including computer aided virtual screening, repurposed drugs, immunomodulators, vaccines, plasma therapy, miscellaneous adjunct therapies and phage technology to unravel insightful mechanistic pathways of targeting SARS-CoV-2 and host’s intrinsic innate immunity at various checkpoints that aid in the containment of the disease.
Search related documents:
Co phrase search for related documents- active site and adaptive innate: 1, 2
- active site and adaptive innate immune system: 1
- active site and adenosine monophosphate: 1, 2, 3
- active site and low nanomolar: 1, 2, 3, 4
- active site and low nanomolar range: 1, 2
- active site and lung injury: 1, 2
- adaptive innate and adenosine monophosphate: 1
- adaptive innate and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- adaptive innate and mab monoclonal antibody: 1, 2
- adaptive innate immune system and lung injury: 1, 2
- adenosine monophosphate and lung injury: 1, 2
- adenosine monophosphate and lung injury protective role: 1
- low nanomolar and mab monoclonal antibody: 1
- lung injury and mab monoclonal antibody: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date